American Society of Nephrology (ASN)

Kidney Health Initiative Urges Investigators to Include People with Kidney Diseases in Clinical Trials for Coronavirus 2019 (COVID-19) Therapies

9-Jun-2020 1:45 PM EDT, by American Society of Nephrology (ASN)

 

Highlights:

  • People with kidney diseases are often excluded from clinical trials because of the complexity and high morbidity of kidney disease.
  • COVID-19 puts people with kidney diseases at a two to sixteen-fold increased risk of severe symptoms.
  • All investigators should include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19.

  

Newswise — Washington, DC (June 9, 2020) — Clinical trials often exclude people with kidney diseases. This practice could have significant consequences, if continued, during the Coronavirus – 2019 (COVID-19) pandemic and for the 37 million Americans with kidney diseases who are at high risk of severe disease.

Preliminary studies indicate that people with kidney diseases demonstrate an increased risk (two- to sixteen-fold) for developing severe COVID-19 symptoms. These data support US statistics that show acute kidney injury occurs in up to 5% of hospitalized COVID-19 patients and 50-90% of patients in the intensive care unit. An effective response to the COVID-19 pandemic should include people with kidney diseases.

The KHI Board of Directors considered a variety of issues impacting drug and device development in the kidney community during the COVID-19 pandemic and identified inclusion of people with kidney diseases in clinical trials for COVID-19 therapies as central to improving care. The recent statement, written by members of the Board of Directors is titled “Making the Case for Change: Including People with Kidney Diseases in COVID-19 Trials”.

“Given their increased risk, people with kidney diseases deserve to be prioritized in the development of novel therapies for COVID-19,” said Raymond C. Harris, MD, FASN, Co-Chair of KHI, “KHI urges sponsors and investigators to come alongside the US Food and Drug Administration (FDA) and the patient community to expand their research into this vulnerable population.”

The FDA encourages enrollment practices that lead to clinical trials better reflecting the population most likely to use and benefit from the therapy being studied. This can be achieved through novel trial designs or broadening eligibility criteria, when appropriate, to increase enrollment of underrepresented populations. A recent guidance from the FDA titled “COVID-19: Developing Drugs and Biological Products for Treatment or Prevention” explicitly encouraged sponsors to include people with kidney diseases in their COVID-19 trials.   

As the largest consortia in the kidney community and a public-private partnership between the American Society of Nephrology and the FDA, KHI urges all investigators to include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19. This population demonstrates increased risk of exposure, infection, and severe morbidity, and inclusion of people with kidney diseases in trials would benefit all aspects of health care.

Individuals who are interested in learning more about KHI, should contact Melissa West, Acting Vice President for Research, Discovery and Innovation, at mwest@asn-online.org

The Kidney Health Initiative (KHI) is a key part of the newly created ASN Alliance for Kidney Health. KHI is uniquely positioned to realize ASN’s vision of a world without kidney diseases. As a public-private and collaborative partnership with the FDA and more than 100 organizations and companies, KHI catalyzes innovation and the development of safe and effective patient-centered therapies for people living with kidney diseases. Learn more at www.kidneyhealthinitiative.org.

 

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.

 

# # #

 

 




Filters close

Showing results

110 of 2911
Newswise: Obesity a Major Risk for Severe COVID-19 Cases
Released: 13-Aug-2020 4:55 PM EDT
Obesity a Major Risk for Severe COVID-19 Cases
Hackensack Meridian Health

While the U.S. Centers for Disease Control and Prevention (CDC) advises that people of any age can contract COVID-19, obesity has emerged among the major risk factors for severe cases. With more than 40 percent of Americans classified as obese, experts caution that this is a growing concern.

Newswise: Ophthalmologists Anticipate a School Year Marked by Complaints of Eye Strain
Released: 13-Aug-2020 4:10 PM EDT
Ophthalmologists Anticipate a School Year Marked by Complaints of Eye Strain
American Academy of Ophthalmology (AAO)

The American Academy of Ophthalmology shares back-to-online school checklist to protect kids’ eyes from too much screen time.

Newswise: 240042_web.jpg
Released: 13-Aug-2020 3:05 PM EDT
A quick, cost-effective method to track the spread of COVID-19
Hokkaido University

A group of researchers have demonstrated that, from seven methods commonly used to test for viruses in untreated wastewater, an adsorption-extraction technique can most efficiently detect SARS-CoV-2. This gives us another tool to detect the presence and spread of the COVID-19 pandemic.

Released: 13-Aug-2020 2:40 PM EDT
Technion’s Nanofiber PPE Sticker Now In Mass Production
American Technion Society

The COVID-busting ‘Maya’ sticker developed by Technion researchers has gone into mass production. Comprised of a nanofiber sheet, the unique sticker can be easily adhered to a protective mask, significantly improving its effectiveness against the novel coronavirus.

13-Aug-2020 11:00 AM EDT
Massive, rapid vaccine production will require firms to share information
University of Michigan

As the world rushes to identify safe and effective vaccines and therapeutics to counter the COVID-19 epidemic, attention is turning to the next step: manufacturing these products at enormous scale.

Released: 13-Aug-2020 1:05 PM EDT
Additive Manufacturing for COVID-19
Materials Research Society (MRS)

A new Prospective article—Additive Manufacturing for COVID-19: Devices, Materials, Prospects and Challenges—published in MRS Communications, looks at these critical supply issues and provides an overview of 3D printing and how coupling the tools in additive manufacturing (AM) and advanced materials has provided a viable alternative for rapid production and distribution of PPEs and medical devices.

Newswise: Busting Up the Infection Cycle of Hepatitis B
Released: 13-Aug-2020 12:50 PM EDT
Busting Up the Infection Cycle of Hepatitis B
University of Delaware

Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the “spiky ball” that encloses the virus’s genetic blueprint. They examined how the capsid—a protein shell that protects the blueprint and also drives the delivery of it to infect a host cell—assembles itself. Scientists believe that the capsid is an important target in developing drugs to treat hepatitis B, a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Newswise: 240097_web.jpg
Released: 13-Aug-2020 12:05 PM EDT
Stay-at-home orders significantly associated with reduced spread of COVID-19, study finds
Brown University

Across the globe, COVID-19 has infected more than 18 million people to date and has killed hundreds of thousands -- and the United States has been hit especially hard.

Released: 13-Aug-2020 11:45 AM EDT
COVID-19 Symptom Tracker Ensures Privacy During Isolation
Georgetown University Medical Center

An online COVID-19 symptom tracking tool developed by researchers at Georgetown University Medical Center ensures a person’s confidentiality while being able to actively monitor their symptoms. The tool is not proprietary and can be used by entities that are not able to develop their own tracking systems.

Newswise: Support for telehealth and mobile health monitoring rises since COVID, study says
Released: 13-Aug-2020 11:25 AM EDT
Support for telehealth and mobile health monitoring rises since COVID, study says
University of Alabama Huntsville

Support for telehealth and mobile health monitoring has risen among healthcare workers and consumers since the rise of the COVID-19 pandemic, according to a new study. Dr. Emil Jovanov, a pioneer in the wearable health monitoring field from The University of Alabama in Huntsville (UAH), participated and was a coauthor.


Showing results

110 of 2911

close
2.70915